Moderna begins trial of ‘next-gen booster’ Covid vax
New York, March 16 : Biotechnology company Moderna announced that the first participants have been dosed in the Phase 1 study of mRNA-1283, the company’s next generation Covid-19 vaccine candidate.This Phase 1 dose-ranging study will assess the safet…
